ZCM
ANIK icon

Zebra Capital Management’s Anika Therapeutics ANIK Stock Holding History

Zebra Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5,455
Closed -$236K – 183
2021
Q2 		$236K Sell
5,455
-589
-10% -$25.1K 0.28% 126
2021
Q1 		$247K Buy
+6,044
New +$229K 0.27% 124
2020
Q1 		– Sell
-4,892
Closed -$254K – 230
2019
Q4 		$254K Buy
4,892
+315
+7% +$18.3K 0.23% 190
2019
Q3 		$252K Buy
+4,577
New +$235K 0.28% 137

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
TI
Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Zebra Capital Management's ANIK Position: Q3 2021 in Review

Zebra Capital Management sold out of Anika Therapeutics (ANIK) in Q3 2021, closing a stake of 5,455 shares — an estimated $236K sold.

Zebra Capital Management first reported a position in ANIK in Q3 2019 and held it in 4 quarters. The position peaked at $254K in Q4 2019. 131 funds tracked by Wall St. Rank hold ANIK as of Q3 2021.

  • Zebra Capital Management reported no remaining Anika Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Zebra Capital Management sold 5,455 Anika Therapeutics shares in Q3 2021, an estimated $236K.
  • Zebra Capital Management first reported a position in Anika Therapeutics in Q3 2019 and held it in 4 quarters.
  • Zebra Capital Management's Anika Therapeutics position peaked at $254K in Q4 2019.
  • 131 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2021.

Based on Zebra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.